2007
DOI: 10.1007/s11010-007-9585-4
|View full text |Cite
|
Sign up to set email alerts
|

SMAD3 inhibits SF-1-dependent activation of the CYP17 promoter in H295R cells

Abstract: Cytochrome P450c17, encoded by the CYP17 gene, is a component of 17alpha-hydroxylase/17,20 lyase which catalyses 17alpha-hydroxylation of pregnenolone or progesterone, required for glucocorticosteroid and androgen synthesis. It has been reported that transforming growth factor beta (TGF-beta) decreases both basal and cAMP-stimulated levels of CYP17 mRNA, but the mechanism of TGF-beta action on CYP17 expression remains unknown. We investigated an inhibitory effect of TGF-beta on CYP17 expression in H295R cells … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
8
1

Year Published

2009
2009
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 32 publications
2
8
1
Order By: Relevance
“…It has been proved that TGF-β1 inhibits the promoter activity via the Smad2 signalling pathway in human trophoblast cells [44]. Moreover, the orphan receptor steroidogenic factor-1 (SF-1) binding site has been identified as the response element in the proximal promoter PII of the rat aromatase gene [45], and TGF-β1 has been proved to inhibit SF-1 expression both at the transcriptional and translational levels in the mouse adrenocortical cell Y-1 [46] and human adrenocortical cell H295R [47].…”
Section: Discussionmentioning
confidence: 99%
“…It has been proved that TGF-β1 inhibits the promoter activity via the Smad2 signalling pathway in human trophoblast cells [44]. Moreover, the orphan receptor steroidogenic factor-1 (SF-1) binding site has been identified as the response element in the proximal promoter PII of the rat aromatase gene [45], and TGF-β1 has been proved to inhibit SF-1 expression both at the transcriptional and translational levels in the mouse adrenocortical cell Y-1 [46] and human adrenocortical cell H295R [47].…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, the repression of the basal promoter activity of P450c17 with active ALK5 expression may be related to the inhibition of SF-1 and LRH-1 transactivation by ALK5 signaling. Consistent with this speculation, Smad3 has been reported to inhibit SF-1-induced P450c17 promoter activity in adrenocortical cells [44].…”
Section: Discussionsupporting
confidence: 57%
“…Moreover, TGF-β1 was confirmed to enhance SF1 (a nuclear receptor NR5A subfamily member) and LRH-1 (liver receptor homolog 1) expression in GCs treated with FSH [46]. However, in human adrenocortical cells, TGF-β1 suppresses endogenous SF1 levels and the overexpression of SMAD3 inhibits SF1 binding to the CYP17 promotor [47]. Additionally, SF1 was required for TGF-β3-induced CYP19A1 expression and E2 release, whilst TGF-β3 enhanced the binding of SF1 to the endogenous ovary-specific CYP19A1 type II promoter [48].…”
Section: Discussionmentioning
confidence: 99%